Published in J Biol Chem on February 12, 2008
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal (2009) 1.85
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Protection by vascular prostaglandin E2 signaling in hypoxic-ischemic encephalopathy. Exp Neurol (2014) 1.46
Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax (2015) 1.46
E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther (2013) 1.28
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab (2008) 1.25
Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. J Virol (2009) 1.00
The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev (2011) 0.99
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. Int Immunopharmacol (2010) 0.97
Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol (2012) 0.96
Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res (2010) 0.94
A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E2 pathway. Clin Exp Allergy (2009) 0.91
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci (2014) 0.90
The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A₂ via GPR120 receptor to produce prostaglandin E₂ and plays an anti-inflammatory role in macrophages. Immunology (2014) 0.89
Prostaglandin E2-induced IL-23p19 subunit is regulated by cAMP-responsive element-binding protein and C/AATT enhancer-binding protein β in bone marrow-derived dendritic cells. J Biol Chem (2012) 0.88
Analysis of genes isolated from plated hemocytes of the Pacific oyster, Crassostreas gigas. Mar Biotechnol (NY) (2008) 0.87
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. Trends Endocrinol Metab (2012) 0.85
Fractalkine depresses cardiomyocyte contractility. PLoS One (2013) 0.81
Progress in multiple sclerosis genetics. Curr Genomics (2012) 0.81
Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue. J Lipid Res (2014) 0.81
Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac Hypertrophy. J Diabetes Res (2016) 0.80
EP4 Receptor-Associated Protein in Macrophages Ameliorates Colitis and Colitis-Associated Tumorigenesis. PLoS Genet (2015) 0.78
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease. Curr Immunol Rev (2015) 0.78
The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin Sensitivity. PLoS One (2015) 0.77
Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes. PLoS One (2016) 0.75
Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation (2017) 0.75
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. ACS Chem Neurosci (2016) 0.75
A network pharmacology approach to establish the pharmacological mechanism of JiaWeiXianJiTang on inflammatory bowel disease. Biomed Rep (2017) 0.75
Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E2 receptor EP4. Kidney Res Clin Pract (2017) 0.75
Prostaglandin E receptor-4 receptor mediates endothelial barrier-enhancing and anti-inflammatory effects of oxidized phospholipids. FASEB J (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage activation and polarization. Front Biosci (2008) 11.17
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell (1995) 7.55
An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods (2001) 6.68
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell (2000) 6.07
Prostaglandin E receptors. J Biol Chem (2007) 5.29
The ankyrin repeat as molecular architecture for protein recognition. Protein Sci (2004) 5.07
Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci (2005) 5.01
Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J (2003) 4.22
The precursor of NF-kappa B p50 has I kappa B-like functions. Cell (1992) 3.82
p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction. Genes Dev (1993) 3.64
The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest (2002) 3.21
Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry (2006) 3.07
Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J (2004) 3.01
Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev (2007) 2.75
Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med (1994) 2.69
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature (1997) 2.56
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation (2006) 2.34
The product of fem-1, a nematode sex-determining gene, contains a motif found in cell cycle control proteins and receptors for cell-cell interactions. Cell (1990) 2.33
Bone marrow-derived macrophages: development and regulation of differentiation markers by colony-stimulating factor and interferons. J Immunol (1985) 2.29
NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell (2003) 2.08
TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature (1999) 2.01
Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol (2002) 1.89
Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105. Mol Cell Biol (2004) 1.86
Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem (2002) 1.80
Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J Exp Med (1998) 1.79
betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol (2003) 1.69
Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis. J Biol Chem (2001) 1.62
Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol (2001) 1.56
Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol (2004) 1.56
The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res (2007) 1.56
Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des (2006) 1.54
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A (2002) 1.51
NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol (2003) 1.49
Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J Biol Chem (2006) 1.45
Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem (2001) 1.44
Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res (2005) 1.37
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood (2004) 1.35
The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol (2004) 1.32
Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol (2005) 1.31
Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res (2004) 1.26
Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol (2006) 1.23
Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J Immunol (2006) 1.20
The human cot proto-oncogene encodes two protein serine/threonine kinases with different transforming activities by alternative initiation of translation. J Biol Chem (1993) 1.18
A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res (2006) 1.16
Persistent activation of nuclear factor-kappaB by interleukin-1beta and subsequent inducible NO synthase expression requires extracellular signal-regulated kinase. Arterioscler Thromb Vasc Biol (2001) 1.00
Prostaglandin E2 augments IL-10 signaling and function. J Immunol (2006) 0.96
Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages. FEBS Lett (1998) 0.95
The murine fem1 gene family: homologs of the Caenorhabditis elegans sex-determination protein FEM-1. Genomics (1998) 0.95
Differential mRNA expression of prostaglandin receptor subtypes in macrophage activation. Prostaglandins Leukot Essent Fatty Acids (2002) 0.94
Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol (2003) 0.94
Abnormal glucose homeostasis and pancreatic islet function in mice with inactivation of the Fem1b gene. Mol Cell Biol (2005) 0.93
Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Oncogene (1999) 0.91
EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Ann Rheum Dis (2004) 0.88
Casper/c-FLIP is physically and functionally associated with NF-kappaB1 p105. Biochem Biophys Res Commun (2003) 0.85
Prostaglandin E2 downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem (2007) 0.84
Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway. Circ Res (2005) 0.84
FEM1A is a candidate gene for polycystic ovary syndrome. Gynecol Endocrinol (2005) 0.80
The Fem1a gene is downregulated in Rhabdomyosarcoma. Tumour Biol (2005) 0.79
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation (2007) 4.20
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem (2008) 4.08
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation (2003) 3.73
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med (2004) 3.69
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation (2007) 3.51
Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res (2008) 3.47
Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem (2007) 3.06
Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem (2002) 3.05
Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2006) 3.01
Inflammation in atherosclerosis: transition from theory to practice. Circ J (2010) 2.98
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med (2012) 2.92
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol (2010) 2.90
Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol (2011) 2.83
Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation (2006) 2.68
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res (2007) 2.66
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med (2002) 2.59
Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation (2004) 2.58
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology (2003) 2.53
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol (2004) 2.46
Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45
Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation (2002) 2.40
Molecular imaging of cardiovascular disease. Circulation (2007) 2.33
Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension (2003) 2.32
Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) (2006) 2.31
Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.28
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation (2003) 2.28
Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation (2004) 2.24
MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest (2012) 2.24
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol (2009) 2.20
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging (2009) 2.17
The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem (2002) 2.17
Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation (2008) 2.12
Adaptive immunity and atherosclerosis. Clin Immunol (2009) 2.08
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07
Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation (2005) 2.05
Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis (2004) 2.02
Clinical problem-solving. A bitter tale. N Engl J Med (2004) 2.02
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation (2005) 2.01
Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 2.00
Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol (2005) 1.98
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation (2008) 1.97
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A (2006) 1.95
Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA (2002) 1.95
ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest (2008) 1.92
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension (2006) 1.91
The Krüppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem (2002) 1.90
Atherosclerosis and proteinase activation. Cardiovasc Res (2005) 1.88
Retracted Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res (2008) 1.85
Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.84
Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation (2009) 1.84
Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest (2004) 1.82